News & Events
IFM weighs in on cGAS/STING inhibitors in latest issue of Nature Biotechnology
IFM Therapeutics and its newest subsidiary, IFM Due, appeared in the March 2019 Issue of Nature Biotechnology as part of a feature on the inhibition of the cGAS/STING pathway.
In a wide-ranging conversation with author Cormac Sheridan, IFM CEO Gary Glick provided insights into the pathway’s role in disease and highlighted the potential therapeutic opportunities, from rare disorders with genetic linkages to cGAS/STING, to broader chronic diseases.
View the full story, “Drug developers switch gears to inhibit STING," in Nature Biotechnology.